Download our key corporate publications below.
From concept to reality – developing biosimilar medicines
Biosimilars are approved via stringent regulatory pathways by the same regulatory authorities, such as the EMA or the US FDA, that approve reference medicines. They are manufactured with the same quality standards that are used for reference medicines.
Learn more about how the stages of biosimilar development generate the totality of evidence, tailored to each molecule
The Sandoz role in addressing AMR
Antimicrobial resistance (AMR) is an increasingly serious threat to global public health, according to the WHO. Sandoz is driving sustainable, multi-stakeholder solutions to combat AMR.
Biosimilar white paper
Improving Access to Essential and Affordable Biologic Medicines in Europe.
A Sandoz Europe white paper.
